Ironwood Pharmaceuticals Inc (IRWD) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
the bull case· 2
9
disclosed supplier and customer ties in SEC filings
sec filingsedgar210
managers reporting a position in the latest quarterly filings
13fJun 30 '26the bear case· 4
6 of 8
recent reports where the move came in under the options implied range
earnings historyimplied vs realized11 of 25
of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '264
of the funds on file reporting a position in IRWD
n-portas of Jun 30 '260.22%
of State Street SPDR S&P Biotech ETF's assets the largest fund weight on file
n-portJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 9 '26 report. Not a forecast, not advice.
Of the 6 companies Ironwood Pharmaceuticals Inc moves with most closely, none share its SEC classification.
Measured against 126 trading days of our own closes. Co-movement, not cause.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.
tall tick = annual report · 1 on record
IRWD (Ironwood Pharmaceuticals Inc) has 3 disclosed suppliers and 6 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.
Ironwood Pharmaceuticals Inc
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
High 4.35 at 7:45 pm ET, low 4.18 at 6:15 am ET.
210 managers report a position worth $679.0M between them, and 22 of them hold 80% of it.